The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000904370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
2/07/2026
Date registered
Help: Date registered
22/07/2026
Date last updated
Help: Date last updated
22/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
22/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The impact of light therapy (photobiomodulation) on severe oral mucositis (painful mouth sores) in adults undergoing allogeneic stem cell transplant
Scientific title
Evaluation of photobiomodulation for preventing severe oral mucositis in allogeneic haematopoietic stem cell transplant: a before-and-after implementation study in an Australian hospital
Additional trial identifiers [1] 317759 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Oral mucositis 342655 0
Allogeneic haematopoietic stem cell transplant 342801 0
Condition category
Condition code
Oral and Gastrointestinal 338795 338795 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Cancer 338924 338924 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
In the intervention group, participants will receive Photobiomodulation (PBM) using the THOR Model LX2.3 unit (THOR Photomedicine Ltd, Chesham, UK).

The THOR LX2.3 is a TGA-approved device for the management of oral mucositis and consists of:

1. Extra-oral 104 Diode LED Cluster Probe
The probe contains two types of LED:
56 × 660 nm LEDs (average power 10 mW per LED)
48 × 850 nm LEDs (average power 30 mW per LED)
Total power output: 2000 mW
Average irradiance: 45 mW/cm²

2. Intra-oral LED Lollipop Probe
The probe contains two types of LED:
18 × 660 nm LEDs (average power 80 mW per LED)
23 × 850 nm LEDs (average power 60 mW per LED)
Total power output: 2800 mW
Average irradiance: 50 mW/cm²

The treatment protocol is derived from the World Association for Photobiomodulation Therapy (WALT) Position Statement 2022 recommendations for the prevention of oral mucositis.

PBM will be delivered to three extra-oral sites and two intra-oral sites, with treatment applied for 60 seconds per site. Each daily PBM session will therefore last 5 minutes in total, comprising:

PBM is delivered to 3 extra-oral and 2 intra-oral sites for 60 seconds per site (5 minutes total treatment time). The delivered fluence is 2.7 J/cm² at each extra-oral site and 3.0 J/cm² at each intra-oral site. Based on total device outputs of 2.0 W and 2.8 W respectively, total energy delivered is 360 J to the extra-oral sites and 336 J to the intra-oral sites, for a total daily energy delivery of 696 J.

PBM will be administered within 30–120 minutes prior to each chemotherapy dose.

Treatment will commence on the first day of conditioning chemotherapy (Day -6) and continue until Day +2 following haematopoietic stem cell infusion, corresponding to a maximum treatment duration of 9 consecutive days. The intervention will be delivered by nursing staff who have completed competency-based training in the use of the PBM device. Fidelity of intervention delivery will be monitored using a daily treatment record completed by nursing staff documenting treatment completion, treatment timing, and any missed treatment sessions.

This is a non-randomised study comprising separate control and intervention cohorts. Participants recruited prior to implementation of the PBM service will receive usual care and will form the control group (n=39). This cohort will be recruited during the period required for service implementation, including procurement of the PBM device and staff training. We anticipate this implementation period will be approximately nine months.
Following implementation of the PBM service, a separate cohort of participants (n=39) will be recruited to receive PBM in addition to usual care and will form the intervention group.
Allocation to the control or intervention group will therefore not be randomised. Group assignment will be determined by the timing of recruitment relative to implementation of the PBM service, with participants recruited before implementation assigned to the control group and participants recruited after implementation assigned to the intervention group.
Intervention code [1] 334594 0
Treatment: Devices
Description of the comparator or control
Usual care of oral mucositis at the RAH is achieved through basic oral care, as outlined in the EVIQ guidelines for oral mucositis.
• inspect the mouth daily and immediately report any adverse changes
• if possible, see a dentist prior to commencing treatment to eliminate possible sources of oral mucosal injury, e.g., ill-fitting dentures, broken teeth
• drink adequate amounts of water to keep the mouth moist (within limitations of fluid restrictive diets where necessary)
• keep lips lubricated (e.g., with lip balm or lip cream)
• avoid using lip balms or creams that are hydrophobic or water-repelling (e.g., have a high content of paraffin or petroleum jelly)
• use a soft toothbrush or swab four times a day, after meals and before sleep (change the toothbrush monthly)
• use a mild, fluoride-containing toothpaste
• if in the habit of using dental floss or inter-dental brushes, continue to do so daily; if this is not already habitual, do not start it while on cancer therapy as it can damage the epithelial barrier, thus increasing the risk of developing mucositis/stomatitis
• rinse mouth with an alcohol-free mouthwash following brushing; and try to avoid eating/drinking for about 30 minutes after rinsing
• remove dentures before performing oral care; brush dentures with toothpaste and rinse with water; clean/swab the gums
• avoid painful stimuli (e.g., smoking, alcohol, acidic foods [such as tomatoes and citrus], hot drinks, spicy, hot, raw and crusty foods, fizzy drinks and too much salt).

Additionally, patients who are receiving melphalan based conditioning regimens currently receive cryotherapy to prevent oral mucositis. Cryotherapy is delivered during melphalan infusion.
Control group
Active

Outcomes
Primary outcome [1] 345996 0
Incidence of severe oral mucositis (grade 3-4) (Effectiveness RE-AIM framework)
Timepoint [1] 345996 0
Daily during inpatient admission until day of hospital discharge
Primary outcome [2] 346216 0
Duration of severe oral mucositis (grade 3-4) (Effectiveness RE-AIM framework)
Timepoint [2] 346216 0
Daily during inpatient hospital admission
Secondary outcome [1] 464071 0
Patient-reported quality of life (Effectiveness RE-AIM framework)
Timepoint [1] 464071 0
Baseline, Daily during hospital admission until day of discharge
Secondary outcome [2] 464092 0
Patient reported quality of life (Effectiveness RE-AIM framework)
Timepoint [2] 464092 0
Day of hospital admission, day +25 after stem cell transplant, day +100 after stem cell transplant
Secondary outcome [3] 464093 0
Modality of nutritional provision (Effectiveness RE-AIM framework)
Timepoint [3] 464093 0
Retrospective over course of hospital admission
Secondary outcome [4] 464094 0
Treatment protocol variations (Effectiveness RE-AIM framework)
Timepoint [4] 464094 0
Retrospective over course of hospital admission
Secondary outcome [5] 464095 0
Analgesia requirements (Effectiveness RE-AIM framework)
Timepoint [5] 464095 0
Retrospective over course of hospital admission
Secondary outcome [6] 464096 0
Transplant-related complications (Effectiveness RE-AIM framework)
Timepoint [6] 464096 0
Retrospective over course of hospital admission
Secondary outcome [7] 464097 0
Length of hospital stay (Effectiveness RE-AIM framework)
Timepoint [7] 464097 0
At hospital discharge
Secondary outcome [8] 465036 0
Cost benefit analysis (Maintenance RE-AIM framework)
Timepoint [8] 465036 0
At hospital discharge
Secondary outcome [9] 465038 0
Quality-adjusted life years (QALY) (Maintenance RE-AIM framework)
Timepoint [9] 465038 0
Baseline, day+25, day+100
Secondary outcome [10] 465039 0
Participation rate (Reach RE-AIM framework)
Timepoint [10] 465039 0
End of study recruitment
Secondary outcome [11] 465042 0
Fidelity to Photobiomodulation intervention protocol (Adoption RE-AIM framework)
Timepoint [11] 465042 0
At hospital discharge
Secondary outcome [12] 465043 0
Clinical adoption (Adoption RE-AIM framework)
Timepoint [12] 465043 0
At end of study recruitment
Secondary outcome [13] 465044 0
Participant acceptability (implementation RE-AIM framework)
Timepoint [13] 465044 0
Collected on each day PBM treatment is delivered (9 days total)
Secondary outcome [14] 465045 0
Clinician acceptability (Implementation RE-AIM framework)
Timepoint [14] 465045 0
Collected on each day PBM treatment is delivered (9 days total)

Eligibility
Key inclusion criteria
18 years or older
undergoing allo-HSCT at the Royal Adelaide Hospital.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Are unable to give written informed consent
Are unable to comprehend or record the self-reporting questionnaires, which will be used to assess quality of life
Have a medical history of epilepsy or sensitivity to flashing lights
Are intubated and ventilated via endotracheal tube
Have a secondary malignancy in the oral cavity or on the face (in the area of treatment) which is not/has not actively been treated.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
A single-centre, prospective before-and-after implementation study using the Re-AIM framework will be conducted.
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Published data indicate a weighted baseline incidence of 44% in allo-HSCT recipients in an Australian transplant centre. Based on published evidence supporting the efficacy of PBM, we anticipate a risk ratio of 0.35. Using a comparison of two independent proportions with a one-sided a of 0.05,80% power and adjusted for a 20%non-response rate, the required sample size is 39 participants per group (78 total). This sample size provides adequate power to detect the anticipated reduction in severe oral mucositis incidence in favour of PBM.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 29750 0
The Royal Adelaide Hospital - Adelaide
Recruitment postcode(s) [1] 46096 0
5000 - Adelaide

Funding & Sponsors
Funding source category [1] 322298 0
Hospital
Name [1] 322298 0
Royal Adelaide Hospital Haematology Department and Clinical Trials Unit Grant
Country [1] 322298 0
Australia
Primary sponsor type
Hospital
Name
The Royal Adelaide Hospital
Address
Country
Australia
Secondary sponsor category [1] 325221 0
None
Name [1] 325221 0
Address [1] 325221 0
Country [1] 325221 0
Other collaborator category [1] 284010 0
University
Name [1] 284010 0
Adelaide University
Address [1] 284010 0
Country [1] 284010 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320809 0
Central Adelaide Local Health Network HREC
Ethics committee address [1] 320809 0
Ethics committee country [1] 320809 0
Australia
Date submitted for ethics approval [1] 320809 0
13/04/2026
Approval date [1] 320809 0
18/06/2026
Ethics approval number [1] 320809 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151710 0
Mr Samuel Bushaway
Address 151710 0
The Royal Adelaide Hospital, Port Road, Adelaide, South Australia, 5000
Country 151710 0
Australia
Phone 151710 0
+61 434228738
Fax 151710 0
Email 151710 0
Contact person for public queries
Name 151711 0
Samuel Bushaway
Address 151711 0
The Royal Adelaide Hospital, Port Road, Adelaide, South Australia, 5000
Country 151711 0
Australia
Phone 151711 0
+61 434228738
Fax 151711 0
Email 151711 0
Contact person for scientific queries
Name 151712 0
Samuel Bushaway
Address 151712 0
The Royal Adelaide Hospital, Port Road, Adelaide, South Australia, 5000
Country 151712 0
Australia
Phone 151712 0
+61 434228738
Fax 151712 0
Email 151712 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval    MyIP22752_Bushaway_ Ethics and Governance.docx.pdf.pdf
Study protocol    2026HRE00055 PBM Protocol V2.1 21_06_26 CLEAN.pdf
Informed consent form    2026HRE00055 Participant information consent from CLEAN V1.4 12_06_26.docx


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.